Citadel Investment’s Griffin moves away from Convertibles

September 20th, 2009
| More
Ken Griffin, President and CEO of Citadel Investment Group, is shifting his $13 billion hedge fund firm away from convertible-bonds, the trademark strategy that marked his start in the industry 22 years ago. According to a recent Bloomberg article, last year the convertible and relative-values strategies lost 55%.

To diversify its business, over the past year Citadel has hired 70 people to operate a new investment banking initiative that seeks to compete with Wall Street Banks. In addition, the hedge fund manager has started three new hedge funds focused on macroeconomic trends, equities, and convertible bonds.

Citadel’s flagship funds, Kensington and Wellington, have returned approximately 52% through September 1 but still need an additional 46% return in order to be healthy enough to start collecting performance fees again.
See Source
For Detailed Investor Profiles on these Investors, click below:
Citadel Investment Group
Related People: Brandon Haley; Becket Wolf; David Grossman; David Hensle; Derek Kaufman; Jeff Runnfeldt; Kaveh Alamouti; Kenneth Griffin; Mark Stainton; Ryan Garino; Steve Weller
Related Entities: Citadel Alternative Asset Management; Citadel Equity Fund; Citadel Kensington; Citadel Wellington; Equiduct; New Castle Re; Sowood Capital*
Related Article Tags: Multi-Strategy, Long Short, Equity, Debt and Global Macro Hedge Fund News

Add a Comment

More Recent Headlines

C12 Capital Management Launches to Manage Barclays’s Troubled Mortgage Assets

Yahoo CEO Bartz Has a Lot of Explaining to Do

Wells Fargo’s Commercial Portfolio set to Explode?

Hedgeable.com Launches with Search for America's Worst Investor

Elliott Management, WestSpring Advisors, Marshall Wace and Scout make New Hires

CEOs, Boards and Management: Welcome to Club Crony

Fortress Investment Group’s Adam Levinson defends $300mm Bonus

Microsoft, Alibaba.com Execs Join Yahoo in Noticeable Share Dumps

D.E. Shaw & Co Expanding into the Middle East

Ramius Capital Group Buys Drug Companies, Moves out of ETFs